{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:32:55Z","timestamp":1787020375454,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic inflammation is thought to be a major causative factor for the development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Tadalafil, a phosphodiesterase type 5 inhibitor (PDE5-I), which has been used for the treatment of BPH-LUTS in daily practice, is known to act at several urinary organs. In this study, focused on the prostate, we examined the effect of tadalafil on the pathological changes and inflammatory factors in a rat nonbacterial prostatitis (NBP) model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Forty ten-month-old male Wistar rats were divided into nonbacterial prostatitis (NBP), NBP with tadalafil treatment (NBP-tadalafil), control, and control treated with tadalafil (control-tadalafil) groups (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910 per group). The NBP and NBP-tadalafil groups were castrated and then received daily subcutaneous 17\u03b2-estradiol for 30\u2009days. The control-tadalafil and NBP-tadalafil groups were administered daily oral tadalafil for 30\u2009days. All rats were then sacrificed and pathological changes and inflammatory factors were assessed in the prostatic tissues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the NBP group, the stroma-to-epithelium (S\/E) ratio in the ventral prostate was significantly higher than in the control group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In the NBP-tadalafil group, the S\/E ratio was significantly lower than in the NBP group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The macrophage levels and the extent of T-cell infiltration in the NBP-tadalafil group were significantly lower than in the NBP group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.005;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively). Compared with the NBP group, tissue concentrations of inflammatory cytokines, such as tumor necrosis factor-\u03b1, interleukin-8, and interleukin-1\u03b2, were significantly downregulated in the NBP-tadalafil group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.005, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tadalafil suppressed stromal predominance and showed anti-inflammatory effects in a rat NBP model in association with downregulation of inflammatory cytokines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-019-0525-x","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T06:57:02Z","timestamp":1571813822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis"],"prefix":"10.1186","volume":"19","author":[{"given":"Mikio","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobufumi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsunemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Hirama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosiyuki","family":"Kekehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"issue":"6","key":"525_CR1","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306\u201314 discussion S1314\u20131305.","journal-title":"Eur Urol"},{"issue":"3","key":"525_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1464-410X.2009.08427.x","volume":"104","author":"KS Coyne","year":"2009","unstructured":"Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352\u201360.","journal-title":"BJU Int"},{"issue":"9","key":"525_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/j.1464-410X.2005.05831.x","volume":"96","author":"MK Li","year":"2005","unstructured":"Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339\u201354.","journal-title":"BJU Int"},{"issue":"5","key":"525_CR4","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.eururo.2006.12.011","volume":"51","author":"G Kramer","year":"2007","unstructured":"Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202\u201316.","journal-title":"Eur Urol"},{"issue":"2","key":"525_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2125.2010.03828.x","volume":"72","author":"S Uckert","year":"2011","unstructured":"Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011;72(2):197\u2013204.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"525_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/phar.1243","volume":"33","author":"MA Cantrell","year":"2013","unstructured":"Cantrell MA, Baye J, Vouri SM. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. Pharmacotherapy. 2013;33(6):639\u201349.","journal-title":"Pharmacotherapy"},{"key":"525_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13401","volume-title":"Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia","author":"Y Homma","year":"2017","unstructured":"Homma Y, Gotoh M, AKawauchi A, Kojima Y, Maeda K, Masumori N, Nagai A, Saitoh T, Sakai H, Takahashi S, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Tokyo: RichHill Medical Inc.; 2017."},{"issue":"1","key":"525_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N\u2019Dow J, Nordling J, de la Rosette JJ. European Association of U: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118\u201340.","journal-title":"Eur Urol"},{"issue":"3","key":"525_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2012.09.006","volume":"63","author":"F Giuliano","year":"2013","unstructured":"Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63(3):506\u201316.","journal-title":"Eur Urol"},{"issue":"10","key":"525_CR10","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1111\/j.1743-6109.2011.02416.x","volume":"8","author":"A Morelli","year":"2011","unstructured":"Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011;8(10):2746\u201360.","journal-title":"J Sex Med"},{"issue":"4","key":"525_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/pros.22584","volume":"73","author":"A Morelli","year":"2013","unstructured":"Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate. 2013;73(4):428\u201341.","journal-title":"Prostate"},{"issue":"5","key":"525_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/pros.23750","volume":"79","author":"H Yamaguchi","year":"2019","unstructured":"Yamaguchi H, Kurita M, Okamoto K, Kotera T, Oka M. Voiding behavior and chronic pelvic pain in two types of rat nonbacterial prostatitis models: attenuation of chronic pelvic pain by repeated administration of tadalafil. Prostate. 2019;79(5):446\u201353.","journal-title":"Prostate"},{"issue":"2","key":"525_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/pros.1126","volume":"49","author":"T Kamijo","year":"2001","unstructured":"Kamijo T, Sato S, Kitamura T. Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats. Prostate. 2001;49(2):122\u201331.","journal-title":"Prostate"},{"issue":"6","key":"525_CR14","doi-asserted-by":"publisher","first-page":"1507 e1515","DOI":"10.1016\/j.urology.2011.02.017","volume":"77","author":"H Tsunemori","year":"2011","unstructured":"Tsunemori H, Sugimoto M, Xia Z, Taoka R, Oka M, Kakehi Y. Effect of the phytotherapeutic agent Eviprostat on inflammatory changes and cytokine production in a rat model of nonbacterial prostatitis. Urology. 2011;77(6):1507 e1515\u201320.","journal-title":"Urology"},{"issue":"4","key":"525_CR15","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/pros.21299","volume":"71","author":"M Sugimoto","year":"2011","unstructured":"Sugimoto M, Oka M, Tsunemori H, Yamashita M, Kakehi Y. Effect of a phytotherapeutic agent, Eviprostat (R), on prostatic and urinary cytokines\/chemokines in a rat model of nonbacterial prostatitis. Prostate. 2011;71(4):438\u201344.","journal-title":"Prostate"},{"issue":"3","key":"525_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.urology.2013.11.033","volume":"83","author":"S Shibuya","year":"2014","unstructured":"Shibuya S, Xia Z, Sugimoto M, Ueda N, Haba R, Kakehi Y. The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate. Urology. 2014;83(3):528\u201334.","journal-title":"Urology"},{"issue":"1","key":"525_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0022-5347(05)67497-6","volume":"164","author":"RB Nadler","year":"2000","unstructured":"Nadler RB, Koch AE, Calhoun EA, Campbell PL, Pruden DL, Bennett CL, Yarnold PR, Schaeffer A. IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol. 2000;164(1):214\u20138.","journal-title":"J Urol"},{"issue":"2","key":"525_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.urology.2009.02.064","volume":"74","author":"L Liu","year":"2009","unstructured":"Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y, Wei Q. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology. 2009;74(2):340\u20134.","journal-title":"Urology"},{"issue":"13","key":"525_CR19","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pros.22686","volume":"73","author":"L Vignozzi","year":"2013","unstructured":"Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73(13):1391\u2013402.","journal-title":"Prostate"},{"issue":"3","key":"525_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pros.22909","volume":"75","author":"M Zarifpour","year":"2015","unstructured":"Zarifpour M, Nomiya M, Sawada N, Andersson KE. Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Prostate. 2015;75(3):233\u201341.","journal-title":"Prostate"},{"issue":"10","key":"525_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/pros.23514","volume":"78","author":"K Okamoto","year":"2018","unstructured":"Okamoto K, Kurita M, Yamaguchi H, Numakura Y, Oka M. Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis. Prostate. 2018;78(10):707\u201313.","journal-title":"Prostate"},{"issue":"1","key":"525_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","volume":"70","author":"M Gacci","year":"2016","unstructured":"Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, Porst H, Roehrborn C, Stief C, Giuliano F. Latest evidence on the use of Phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70(1):124\u201333.","journal-title":"Eur Urol"},{"issue":"2","key":"525_CR23","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.juro.2012.07.141","volume":"189","author":"M Nomiya","year":"2013","unstructured":"Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M, Keys T, Peyton C, Yamaguchi O, Andersson KE. Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol. 2013;189(2):754\u201361.","journal-title":"J Urol"},{"issue":"4","key":"525_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/nau.22732","volume":"35","author":"Y Kawai","year":"2016","unstructured":"Kawai Y, Oka M, Yoshinaga R, Fuchikami C, Oyama T. Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction. Neurourol Urodyn. 2016;35(4):444\u20139.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"525_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jsxm.2019.02.017","volume":"16","author":"R Yoshinaga","year":"2019","unstructured":"Yoshinaga R, Fukui T, Yoshifuji M, Fujimura M, Oyama T, Oka M. Comparison of the effects of Tadalafil and \u03b11-Adrenoceptor antagonists on spontaneous seminal emission and electrical field stimulation-induced seminal vesicle contraction in rats. J Sex Med. 2019;16(5):680\u201390.","journal-title":"J Sex Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-019-0525-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-019-0525-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-019-0525-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T19:05:37Z","timestamp":1603307137000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-019-0525-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1186\/s12894-019-0525-x","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"15 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental procedures complied with the Guidelines of Animal care of Kagawa University, and was approved (K16649\u20131) by the ethical board of Kagawa University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}